Grifols Recombinant Protein Contract Development and Manufacturing Organization (CDMO) has three decades of experience manufacturing recombinant proteins. Recently, the business expanded its focus to apply its experience to producing therapeutic proteins for biopharmaceutical organizations. Its new GMP consolidated manufacturing facility (CMF) on its Emeryville, California, campus supports this expansion.

The CMF facility houses multiproduct production and features state-of-the-art equipment, including a distributed control system and a central data historian. We sat down with six diverse experts at Grifols Recombinant Protein CDMO to discuss how the group’s legacy and recent investments support its future in providing recombinant protein CDMO services.

READ MORE BY FILLING OUT THE FORM >>>>>